Journal of Clinical Oncology, Vol 14, 2054-2060, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial

DH Johnson, DM Paul, KR Hande, Y Shyr, C Blanke, B Murphy, M Lewis and RF De Vore 3rd
Department of Medicine, Vanderbilt University Medical School, Nashville, TN, USA. david.johnson@mcmail.vanderbilt.edu

PURPOSE: Studies conducted by the Eastern Cooperative Oncology Group (ECOG) indicate both paclitaxel and carboplatin are associated with an improvement in 1-year survival in patients with stage IV non-small-cell lung cancer (NSCLC). Based on these findings, a phase II trial of these agents in combination was conducted in patients with advanced NSCLC. PATIENTS AND METHODS: Eligibility included previously untreated stage IIIB or IV NSCLC patients with a good performance status (PS). Paclitaxel (135 or 175 mg/m2) was administered by 24-hour infusion on day 1, followed by a 1-hour infusion of carboplatin on day 2 (300 mg/m2 or dosed to an area under the concentration-time curve [AUC] of 6 mg/mL.min). Treatment was repeated every 28 days for a total of six cycles. Hematopoietic growth factors were not routinely used. RESULTS: Among 51 eligible patients, there were no complete and 14 partial responses, for an overall response rate of 27% (95% confidence interval [CI], 17% to 41%). The median progression-free survival time was 23.8 weeks (range, 12.1 to 73.9) and median survival time, 38 weeks. The survival rate at 1 year was 32%. Grade 3 or 4 granulocytopenia and thrombocytopenia were observed in 47% and 3%, respectively, of the 184 treatment cycles administered. The most common nonhematologic toxicities included nausea and emesis, neuropathy, and arthralgia/myalgia. CONCLUSION: Paclitaxel plus carboplatin is a moderately active regimen in patients with advanced NSCLC and warrants comparison with existing cisplatin-based regimens in a prospective randomized trial. The toxicities of this regimen are well tolerated in patients with a good PS.

This article has been cited by other articles:

				D. -W. Kim, S. -Y. Kim, H. -K. Kim, S. -W. Kim, S. W. Shin, J. S. Kim, K. Park, M. Y. Lee, and D. S. Heo Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer Ann. Onc., December 1, 2007; 18(12): 2009 - 2014. [Abstract] [Full Text] [PDF]

				C. P. Belani, J. S. Lee, M. A. Socinski, F. Robert, D. Waterhouse, K. Rowland, R. Ansari, R. Lilenbaum, and R. B. Natale Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer Ann. Onc., July 1, 2005; 16(7): 1069 - 1075. [Abstract] [Full Text] [PDF]

				Z. Duan, K. A. Brakora, and M. V. Seiden Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells Mol. Cancer Ther., July 1, 2004; 3(7): 833 - 838. [Abstract] [Full Text] [PDF]

				D. P. Carbone Epidermal Growth Factor Receptor Overexpression: The Importance of Context J. Clin. Oncol., December 1, 2003; 21(23): 4268 - 4269. [Full Text] [PDF]

				S. S. Leong, E. H. Tan, K. W. Fong, E. Wilder-Smith, Y. K. Ong, B. C. Tai, L. Chew, S. H. Lim, J. Wee, K. M. Lee, et al. Randomized Double-Blind Trial of Combined Modality Treatment With or Without Amifostine in Unresectable Stage III Non-Small-Cell Lung Cancer J. Clin. Oncol., May 1, 2003; 21(9): 1767 - 1774. [Abstract] [Full Text] [PDF]

				B. Freidlin, O. S. Breathnach, and B. E. Johnson A Model to Select Regimens for Phase III Trials for Patients with Advanced-Stage Non-Small Cell Lung Cancer Clin. Cancer Res., March 1, 2003; 9(3): 917 - 922. [Abstract] [Full Text] [PDF]

				R. S. Herbst, T. L. Madden, H. T. Tran, G. R. Blumenschein Jr, C. A. Meyers, L. F. Seabrooke, F. R. Khuri, V. K. Puduvalli, V. Allgood, H. A. Fritsche Jr, et al. Safety and Pharmacokinetic Effects of TNP-470, an Angiogenesis Inhibitor, Combined With Paclitaxel in Patients With Solid Tumors: Evidence for Activity in Non-Small-Cell Lung Cancer J. Clin. Oncol., November 15, 2002; 20(22): 4440 - 4447. [Abstract] [Full Text] [PDF]

				R. Rosell, U. Gatzemeier, D. C. Betticher, U. Keppler, H. N. Macha, R. Pirker, P. Berthet, J. L. Breau, P. Lianes, M. Nicholson, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial Ann. Onc., October 1, 2002; 13(10): 1539 - 1549. [Abstract] [Full Text] [PDF]

				P. Kosmidis, N. Mylonakis, C. Nicolaides, C. Kalophonos, E. Samantas, J. Boukovinas, G. Fountzilas, D. Skarlos, T. Economopoulos, D. Tsavdaridis, et al. Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non-Small-Cell Lung Cancer: A Phase III Randomized Trial J. Clin. Oncol., September 1, 2002; 20(17): 3578 - 3585. [Abstract] [Full Text] [PDF]

				G. V. Kornek, K. Haider, W. Kwasny, M. Raderer, B. Schull, T. Payrits, D. Depisch, E. Kovats, F. Lang, and W. Scheithauer Treatment of Advanced Breast Cancer with Docetaxel and Gemcitabine with and without Human Granulocyte Colony-stimulating Factor Clin. Cancer Res., May 1, 2002; 8(5): 1051 - 1056. [Abstract] [Full Text] [PDF]

				Y.-M. Chen, R.-P. Perng, Y.-C. Lee, J.-F. Shih, C.-S. Lee, C.-M. Tsai, and J. Whang-Peng Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated Ann. Onc., January 1, 2002; 13(1): 108 - 115. [Abstract] [Full Text] [PDF]

				K. Kelly, J. Crowley, P. A. Bunn Jr, C. A. Presant, P. K. Grevstad, C. M. Moinpour, S. D. Ramsey, A. J. Wozniak, G. R. Weiss, D. F. Moore, et al. Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non-Small-Cell Lung Cancer: A Southwest Oncology Group Trial J. Clin. Oncol., July 1, 2001; 19(13): 3210 - 3218. [Abstract] [Full Text] [PDF]

				M. A. Socinski, A. B. Sandler, L. L. Miller, P. K. Locker, C. K. Hanover, G. L. Elfring, V. K. Israel, N. Pirotta, and R. B. Natale Phase I Trial of the Combination of Irinotecan, Paclitaxel, and Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., February 15, 2001; 19(4): 1078 - 1087. [Abstract] [Full Text] [PDF]

				M. H. Jagasia, C. J. Langer, D. H. Johnson, F. Yunus, J. S. Rodgers, L. L. Schlabach, A. G. Cohen, Y. Shyr, D. P. Carbone, and R. F. DeVore Weekly Irinotecan and Cisplatin in Advanced Non-Small Cell Lung Cancer: A Multicenter Phase II Study Clin. Cancer Res., January 1, 2001; 7(1): 68 - 73. [Abstract] [Full Text]

				U. Gatzemeier, J. von Pawel, M. Gottfried, G. P. M. t. Velde, K. Mattson, F. DeMarinis, P. Harper, F. Salvati, G. Robinet, A. Lucenti, et al. Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., October 19, 2000; 18(19): 3390 - 3399. [Abstract] [Full Text] [PDF]

				O. S. Breathnach, M. S. Georgiadis, B. S. Schuler, P. Pizzella, V. Llorens, V. Kasturi, S. M. Steinberg, K. O’Neil, C. H. Takimoto, and B. E. Johnson Phase II Trial of Paclitaxel by 96-Hour Continuous Infusion in Combination with Cisplatin for Patients with Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2000; 6(7): 2670 - 2676. [Abstract] [Full Text]

				C. P. Belani Paclitaxel and Docetaxel Combinations in Non-Small Cell Lung Cancer Chest, April 1, 2000; 117(4_suppl_1): 144S - 151S. [Abstract] [Full Text] [PDF]

				Z. Duan, A. J. Feller, R. T. Penson, Bruce. A. Chabner, and M. V. Seiden Discovery of Differentially Expressed Genes Associated with Paclitaxel Resistance Using cDNA Array Technology: Analysis of Interleukin (IL) 6, IL-8, and Monocyte Chemotactic Protein 1 in the Paclitaxel-resistant Phenotype Clin. Cancer Res., November 1, 1999; 5(11): 3445 - 3453. [Abstract] [Full Text] [PDF]

				J. E. Groopman and L. M. Itri Chemotherapy-Induced Anemia in Adults: Incidence and Treatment J Natl Cancer Inst, October 6, 1999; 91(19): 1616 - 1634. [Abstract] [Full Text] [PDF]

				M. H. Cullen, L. J. Billingham, C. M. Woodroffe, A. D. Chetiyawardana, N. H. Gower, R. Joshi, D. R. Ferry, R. M. Rudd, S. G. Spiro, J. E. Cook, et al. Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life J. Clin. Oncol., October 1, 1999; 17(10): 3188 - 3194. [Abstract] [Full Text] [PDF]

				R. F. DeVore, D. H. Johnson, J. Crawford, J. Garst, I. W. Dimery, J. Eckardt, S. G. Eckhardt, G. L. Elfring, L. J. Schaaf, C. K. Hanover, et al. Phase II Study of Irinotecan Plus Cisplatin in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., September 1, 1999; 17(9): 2710 - 2710. [Abstract] [Full Text] [PDF]

				V. Georgoulias, C. Kouroussis, N. Androulakis, S. Kakolyris, M.-A. Dimopoulos, E. Papadakis, D. Bouros, F. Apostolopoulou, C. Papadimitriou, A. Agelidou, et al. Front-Line Treatment of Advanced Non–Small-Cell Lung Cancer With Docetaxel and Gemcitabine: A Multicenter Phase II Trial J. Clin. Oncol., March 1, 1999; 17(3): 914 - 914. [Abstract] [Full Text] [PDF]

				C. P. Belani, C. M. Kearns, E. G. Zuhowski, K. Erkmen, D. Hiponia, D. Zacharski, C. Engstrom, R. K. Ramanathan, M. J. Capozzoli, J. Aisner, et al. Phase I Trial, Including Pharmacokinetic and Pharmacodynamic Correlations, of Combination Paclitaxel and Carboplatin in Patients With Metastatic Non–Small-Cell Lung Cancer J. Clin. Oncol., February 1, 1999; 17(2): 676 - 676. [Abstract] [Full Text] [PDF]

				C. J. Langer and D. S. Ettinger The Burgeoning Role of Paclitaxel in Advanced Pulmonary Malignancy Oncologist, April 1, 1998; 3(2): 67 - 85. [Abstract] [Full Text]